



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
John A. Hey, et al

For Patent For:
Use of Dual H₃/M₂ Antagonists in the
Treatment of Cognition Deficit Disorders

Serial No.: 10/072,340

Filing Date: February 6, 2002

Examiner: To be assigned

Art Unit: To be assigned

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98. Applicants enclose a Form PTO-1449 (one page) listing publications known to applicants that may be relevant to this application.

This Statement is submitted within three months of filing the application.

Publications AL, AM, AQ-AX and BF were cited in the background portion of the specification. AA-AG, BQ and BR disclose H₃ receptor antagonists, while AH-BE, BS and BT disclose muscarinic antagonists; all were cited in the specification (note that BS is the regular patent application

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C., 20231, on March 20, 2002

Anita W. Magatti

Registered Representative

[Signature]
Signature

3/20/02
Date


16000
0420 03-18-02
RECEIVED
APR 14 2002
TECH CENTER 1600/2900
PATENT CASE CN01388K

claiming benefit of US Provisional 60/257,853 cited in the application). AY, AZ and BF, also cited in the specification, relate to test procedures.

Copies of the references are attached.

The examiner is requested to examine the publications, to initial the form PTO-1449 and to return a copy of the initialed form to applicants.

Respectfully submitted,



Anita W. Magatti
Reg. No. 29,825
Attorney for Applicants
(908) 298-5067